Carregant...
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
INTRODUCTION: CD40 is a promising therapeutic target for cancer immunotherapy. In patients with advanced solid malignancies, CD40 agonists have demonstrated some anti-tumor activity and a manageable toxicity profile. A 2(nd) generation of CD40 agonists has now been designed with optimized Fc recepto...
Guardat en:
| Publicat a: | Expert Rev Anticancer Ther |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5533512/ https://ncbi.nlm.nih.gov/pubmed/27927088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14737140.2017.1270208 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|